CNS Pharm Flashcards
What is the NT pathophys of Alzheimer’s disease?
decreased ACh-M
What is the 1a pharm approach in Alzheimer’s disease?
increase ACh activity
What is the NT pathophys of acute/chronic pain?
abnormal PG, ion channels, 5HT, glutamate
What is the NT pathophys of Parkinson’s disease?
decreased striatal DA release (leading to increased ACh and increased GABA inhibition)
This is due to decreased striatal DA release (leading to increased ACh and increased GABA inhibition).
Parkinson’s disease
This is caused by abnormal PG, ion channels, 5HT, glutamate.
acute/chronic pain
This is caused by decreased ACh-M.
Alzheimer’s disease
What is the NT pathophys of seizure disorders?
abnormal VSSC-VSCC, decreased GABA and/or increased glutamate
This is caused by abnormal VSSC-VSCC, decreased GABA and/or increased glutamate.
seizure disorders
What is the 1a pharm approach in Parkinson’s disease?
increased DA activity
What is the 1a pharm approach in acute/chronic pain?
increase ENK activity, increase NE/5HT, decrease PG formation
What is the 1a pharm approach in seizure disorder?
increase GABA activity, block VSSC and VSCC
What is the 1a pharm approach in psychoses?
block D2 and 5HT2a receptors
What is the 1a pharm approach in depression?
increase synaptic levels of 5HT, NE, and DA
What is the 1a pharm approach in mania?
modulate NT activity, block VSSC-VSCC